(Z)-2-chloro-3-phenylpropenoic acid amide | 74305-85-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-2-chloro-3-phenylpropenoic acid amide
• 英文别名: α-chloro-trans-cinnamic acid amide；α-Chlor-trans-zimtsaeure-amid；2-chloro-3-phenylprop-2(Z)-enamide；(Z)-2-chloro-3-phenylprop-2-enamide
• CAS: 74305-85-4
• 化学式: C₉H₈ClNO
• 分子量: 181.622
• InChiKey: CBUADRLVGGSMNQ-VURMDHGXSA-N

物化性质

• 熔点：
  118.5-119.5 °C(Solv: 1,2-dichloroethane (107-06-2))
• 沸点：
  374.2±42.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (Z)-2-chloro-3-phenylpropenoic acid amide 在 氢氧化钾 、 三氯氧磷 作用下， 生成 β-ethoxy-cinnamonitrile
  参考文献：
  名称：

  v. Auwers; Huegel, Journal fur praktische Chemie (Leipzig 1954), 1935, vol. <2> 143, p. 179,185

  摘要：

  DOI：
• 作为产物：
  描述：

  二氯甲基苯 在 ammonium hydroxide 作用下， 生成 (Z)-2-chloro-3-phenylpropenoic acid amide
  参考文献：
  名称：

  Reactions of Ethyl Diazoacetate with Aromatic Compounds Containing Hetero Atoms Attached to the Benzyl Carbon

  摘要：

  DOI：

  10.1021/ja01637a064

文献信息

• Synthesis of dihalohydrins and tri- and tetra-substituted olefins
  申请人：Board of Regents, The University of Texas System

  公开号：US20040143125A1

  公开（公告）日：2004-07-22

  A novel synthesis reaction for highly stereospecific tri- and tetra-substituted olefins is described. A single stereoisomer of stable &agr;-halo-&agr;,&bgr;-ester is produced in high yield by the reaction of aldehyde or ketone with a trihalogenated compound such as trichloroacetate in the presence of CrCl 2 in a solvent. By varying the amount of CrCl 2 used, the stable dihalohydrin intermediate may be obtained as well.

  描述了一种用于高度立体特异性三取代和四取代烯烃的新合成反应。通过醛或酮与三卤代化合物（如三氯乙酸盐）在溶剂中在CrCl2存在下的反应，可以高产率地产生稳定的α-卤代-α，β-酯的单立体异构体。通过改变使用的CrCl2量，也可以获得稳定的二卤水合物中间体。
• Small molecule inhibitors of STAT3 with anti-tumor activity
  申请人：Turkson James

  公开号：US20090069420A1

  公开（公告）日：2009-03-12

  The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

  本发明涉及化合物、含有这些化合物的组合物以及使用这些化合物和组合物作为Stat3信号传导、Stat3二聚化、Stat3-DNA结合、Stat5-DNA结合和/或体内或体外异常细胞生长的抑制剂的方法，例如用作治疗癌症（如乳腺癌）的抗癌剂。本发明的化合物包括但不限于NSC 74859（S3I-201）、NSC 42067、NSC 59263、NSC 75912、NSC 11421、NSC 91529、NSC 263435以及上述的药物可接受的盐和类似物。其他非恶性疾病，其特征为细胞增殖，可以使用本发明的化合物进行治疗，但不限于肝硬化、移植排斥、再狭窄以及以T细胞增殖为特征的疾病，例如自身免疫疾病，如1型糖尿病、狼疮和多发性硬化症。本发明还包括一种用于检测哺乳动物组织中恶性细胞存在的体外筛选测试；一种识别组成Stat3激活、Stat3-DNA结合、Stat5-DNA结合和/或Stat3二聚化抑制剂的方法；以及一种识别抗癌剂的方法。
• Small molecule inhibitors of stat3 with anti-tumor activity
  申请人：Turkson James

  公开号：US20110201576A1

  公开（公告）日：2011-08-18

  The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

  本发明涉及化合物、含有这些化合物的组合物以及使用这些化合物和组合物作为Stat3信号、Stat3二聚化、Stat3-DNA结合、Stat5-DNA结合和/或体内或体外异常细胞增长的抑制剂的方法，例如作为治疗癌症（如乳腺癌）的抗癌剂。本发明的化合物包括但不限于NSC 74859（S3I-201）、NSC 42067、NSC 59263、NSC 75912、NSC 11421、NSC 91529、NSC 263435及其药学上可接受的盐和类似物。本发明还包括使用该化合物治疗其他非恶性疾病，这些疾病以细胞增生为特征，但不限于肝硬化、移植排斥、再狭窄和以T细胞增殖为特征的疾病，例如自身免疫性疾病，如1型糖尿病、红斑狼疮和多发性硬化症。本发明还包括一种体外筛选恶性细胞的方法；一种识别组成性Stat3激活、Stat3-DNA结合、Stat5-DNA结合和/或Stat3二聚化抑制剂的方法；以及一种识别抗癌剂的方法。
• SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY
  申请人：H. Lee Moffitt Cancer Center And Research Institute, Inc.

  公开号：US20140329900A1

  公开（公告）日：2014-11-06

  The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

  本发明涉及化合物、含有这些化合物的组合物以及使用这些化合物和组合物作为Stat3信号通路、Stat3二聚化、Stat3-DNA结合、Stat5-DNA结合和/或体外或体内异常细胞生长的抑制剂的方法，例如作为治疗癌症，如乳腺癌的抗癌剂。本发明的化合物包括但不限于NSC 74859（S31-201）、NSC 42067、NSC 59263、NSC 75912、NSC 11421、NSC 91529、NSC 263435以及其药学上可接受的盐和类似物。其他非恶性疾病，其特征为细胞增殖，可以使用本发明的化合物进行治疗，但不限于肝硬化、移植排斥反应、再狭窄以及T细胞增殖的疾病，例如自身免疫性疾病，如1型糖尿病、狼疮和多发性硬化等。本发明还包括一种用于检测哺乳动物组织中恶性细胞存在的体外筛选测试；一种识别组成性Stat3激活、Stat3-DNA结合、Stat5-DNA结合和/或Stat3二聚化抑制剂的方法；以及一种识别抗癌剂的方法。
• Stoermer; Heymann, Chemische Berichte, 1913, vol. 46, p. 1265
  作者：Stoermer、Heymann

  DOI：——

  日期：——